CD22 Nanobody for High-Affinity B Cell Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for targeting B cells in diseases such as tumors and autoimmune disorders have limitations in specificity and efficacy, particularly in effectively binding to CD22, a protein highly expressed in B cell malignancies.
Innovation Solution
Development of a nanobody or antigen-binding fragment specifically binding to CD22, comprising combinations of CDR1, CDR2, and CDR3 sequences with specific amino acid insertions, deletions, and substitutions, designed to achieve high affinity and specificity for CD22, potentially used in pharmaceutical compositions for treating B cell-related diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional monoclonal antibodies are used to target CD22, then therapeutic effect is achieved, but molecular weight is large and tissue penetration is limited
Solution Approach 1:
The patent extracts only the essential antigen-binding function from the complete antibody molecule by using nanobodies (single-domain antibodies) that contain only the variable domain (VHH) without light chains or Fc regions. This extraction maintains CD22 binding capability while dramatically reducing molecular weight and improving tissue penetration characteristics.
Solution Approach 2:
The patent segments the antibody structure into its minimal functional unit - the single heavy chain variable domain (nanobody) - separating the binding function from the effector functions. This segmentation allows the binding domain to be optimized for penetration while effector functions can be added separately if needed.
2Reliability
If conventional antibodies are used, then CD22 binding is achieved, but affinity and specificity are insufficient for optimal therapeutic effect
Solution Approach 1:
The patent applies local quality by focusing the entire antibody structure's binding capability into a single nanobody domain with optimized CDR regions. The complementarity determining regions (CDR1, CDR2, CDR3) are specifically engineered to achieve high affinity and specificity for CD22, concentrating the binding function rather than distributing it across multiple antibody chains.
3Reliability
If full-length antibodies are used for CD22 targeting, then therapeutic coverage is achieved, but expression and coupling difficulty increases
Solution Approach 1:
The patent uses simplified nanobody constructs that are easier and cheaper to produce than full-length antibodies. The single-domain structure requires simpler expression systems and can be more readily coupled to therapeutic agents, imaging modalities, or other functional molecules, reducing manufacturing complexity while maintaining therapeutic coverage through the concentrated binding activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanobody effectively binds to CD22 with a dissociation constant of no more than 50 nM, providing a potent therapeutic option for B cell malignancies and autoimmune diseases by specifically targeting CD22-expressing cells.
Implementation Method 1
The nanobody effectively binds to CD22 with a dissociation constant of no more than 50 nM
Data Source
AI summary
Provided are an CD22 nano antibody, and a preparation method therefor and an application thereof. The CD22 nano antibody has high affinity with a CD22 protein, and can be used for preparing drugs for treating tumors, autoimmune diseases, etc.